Clinical Trials Directory

Trials / Unknown

UnknownNCT05586048

Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure

Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure: AUGUST-AHF Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
1,200 (estimated)
Sponsor
China Academy of Chinese Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this cohort study is to observe the effectiveness of Yiqi Fumai Lyophilized Injection (YQFM) in patients with acute heart failure (AHF). It mainly aims to assess the effectiveness of YQFM on the 90-day mortality or readmission rate in patients with AHF and compare the results with AUGUST-AHF RCT study. There will be no intervention, but information will be collected during the hospital stay and during the follow-up period of 180 days . Researchers will compare exposed group(patients who received YQFM) and non-exposed group(patients who didn't received YQFM) to see if there is difference on the 90-day mortality or readmission rate.

Detailed description

It mainly aims to assess the effectiveness of YQFM on the 90-day mortality or readmission rate in patients with AHF and compare the results with AUGUST-AHF RCT study. There will be no intervention, but patients will be asked to answer questions(such as scales or reporting of symptoms ) and provide biochemical or imaging tests, as well as undergo regular follow-up. Researchers will compare exposed group(patients who received YQFM) and non-exposed group(patients who didn't received YQFM) to see if there is difference on the 90-day mortality or readmission rate. We will also collect information on medication adherence during the follow-up period and remotely test patients during the follow-up period

Conditions

Interventions

TypeNameDescription
DRUGYiqi Fumai Lyophilized Injection(YQFM)No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM

Timeline

Start date
2023-04-01
Primary completion
2025-11-30
Completion
2025-11-30
First posted
2022-10-19
Last updated
2023-03-10

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05586048. Inclusion in this directory is not an endorsement.